Biology Reference
In-Depth Information
71. Levesque AA, Fanous AA, Poh A, Eastman A. Defective p53 signaling in p53 wild-type tumors
attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1
inhibitors that abrogate DNA damage-induced S and G2 arrest.
Mol Cancer Ther
2008;
:252-62.
72. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent
abrogator of G2 checkpoint function in cancer cells with disrupted p53.
J Natl Cancer Inst
1996;
7
:956-65.
73. Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, et al. A Phase 1 study of UCN-
01 in combination with irinotecan in patients with resistant solid tumor malignancies.
Cancer
Chemother Pharmacol
2011;
88
:1225-37.
74. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as
cancer therapeutics.
Trends Mol Med
2011;
67
:88-96.
75. Sangster-Guity N, Conrad BH, Papadopoulos N, Bunz F. ATR mediates cisplatin resistance in
a p53 genotype-specific manner.
Oncogene
2011;
17
:2526-33.
76. Hurley PJ, Wilsker D, Bunz F. Human cancer cells require ATR for cell cycle progression
following exposure to ionizing radiation.
Oncogene
2007;
30
:2535-42.
77. Alderton GK, Joenje H, Varon R, Borglum AD, Jeggo PA, O'Driscoll M. Seckel syndrome
exhibits cellular features demonstrating defects in the ATR-signalling pathway.
Hum Mol
Genet
2004;
26
:3127-38.
78. Wilsker D, Bunz F. Loss of ataxia telangiectasia mutated- and Rad3-related function poten-
tiates the effects of chemotherapeutic drugs on cancer cell survival.
Mol Cancer Ther
2007;
13
:1406-13.
79. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, et al. The
combined status of ATM and p53 link tumor development with therapeutic response.
Genes
Dev
2009;
6
:1895-909.
80. Toledo LI, Murga M, Zur R, Soria R, Rodriguez A, Martinez S, et al. A cell-based screen
identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.
Nat
Struct Mol Biol
2011;
23
:721-7.
81. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and
characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/
mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.
Mol Cancer
Ther
2008;
18
:1851-63.
82. Charrier JD, Durrant SJ, Golec JM, Kay DP, Knegtel RM, MacCormick S, et al. Discovery of
potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR)
protein kinase as potential anticancer agents.
J Med Chem
2011;
7
:2320-30.
83. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, et al. Selective
killing of ATM- or p53-deficient cancer cells through inhibition of ATR.
Nat Chem Biol
2011;
54
:428-30.
84. Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC, et al. Combining
ATR suppression with oncogenic Ras synergistically increases genomic instability, causing
synthetic lethality or tumorigenesis in a dosage-dependent manner.
Cancer Res
2010;
7
:
70
9693-702.
85. Lam MH, Liu Q, Elledge SJ, Rosen JM. Chk1 is haploinsufficient for multiple functions
critical to tumor suppression.
Cancer Cell
2004;
:45-59.
86. Menoyo A, Alazzouzi H, Espin E, Armengol M, Yamamoto H, Schwartz Jr. S. Somatic
mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors
with microsatellite instability.
Cancer Res
2001;
6
:7727-30.
87. Vassileva V, Millar A, Briollais L, Chapman W, Bapat B. Genes involved in DNA repair are
mutational
61
targets in endometrial cancers with microsatellite instability.
Cancer Res
2002;
:4095-9.
62
